ENLIGHTED Study is a clinical research to test a treatment called padeliporfin VTP for a type of cancer called Upper Tract Urothelial Carcinoma (UTUC). This cancer affects the lining of the kidney or the tube (ureter) that carries urine from the kidney to the bladder. The study aims to treat low-grade (less dangerous) cancer that hasn't spread deeply.

The study is divided into three parts: Induction Treatment Phase, Maintenance Treatment Phase, and Long Term Follow-up Phase. In the Induction Phase, patients might receive up to three treatments, spaced about a month apart, to see if the cancer disappears. If the cancer is not gone after three treatments, the patient will not continue to the next phase. If the treatment works, the patient enters the Maintenance Phase, where their condition is monitored for 12 months, and additional treatments are given if needed. The Long Term Follow-up Phase can last up to 48 months to check for any return of cancer or side effects.

• The study can last up to 5 years.
• Regular check-ups are required during the study.
• Patients will not receive any additional padeliporfin VTP treatment in the Long Term Follow-up Phase.